Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Nagase Diagnostics Co. Ltd. currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct art units and involve 2 distinct examiners. This distribution indicates that the company's diagnostic technologies are being evaluated from multiple technical perspectives. This lack of examiner concentration means that the company must adapt its arguments to suit different individual styles even within the same broad technology area.
Christian L Fronda is the busiest examiner for the portfolio, currently handling 1 pending office action. The presence of 2 distinct examiners and 2 art units for only 2 pending actions shows a lack of concentration in the prosecution. Each application is being handled by a different examiner in a different unit, requiring a tailored approach for each case. Practitioners should note that having 2 distinct art units for only 2 pending actions implies that each application is being scrutinized under different technical standards, requiring a high degree of versatility in prosecution strategy.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FRONDA, CHRISTIAN L | 1 | 82.4% | +14.2% |
| JONES-FOSTER, ERICA NICOLE | 1 | 48.1% | +44.7% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18277967 | TARGET PROTEIN PRODUCTION METHOD | FRONDA, CHRISTIAN L | 15d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18277967 | TARGET PROTEIN PRODUCTION METHOD | FRONDA, CHRISTIAN L | 15d |
| 17623517 | GLYCATED PROTEIN ASSAY REAGENT CONTAINING STABILIZER OF PROTEASE THAT INCREASES OXIDATION-REDUCTION POTENTIAL OF FERROCYANIDE, METHOD FOR ASSAYING GLYCATED PROTEIN, METHOD FOR PRESERVING GLYCATED PROTEIN ASSAY REAGENT, AND METHOD FOR STABILIZING GLYCATED PROTEIN ASSAY REAGENT | JONES-FOSTER, ERICA NICOLE | — |
| Art Unit | Apps |
|---|---|
| 1652 | 1 |
| 1656 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18277967 | TARGET PROTEIN PRODUCTION METHOD | FRONDA, CHRISTIAN L | 1652 | §112 | Final Rejection | 15d | Pending | Aug 18, 2023 |
| 17623517 | GLYCATED PROTEIN ASSAY REAGENT CONTAINING STABILIZER OF PROTEASE THAT INCREASES OXIDATION-REDUCTION POTENTIAL OF FERROCYANIDE, METHOD FOR ASSAYING GLYCATED PROTEIN, METHOD FOR PRESERVING GLYCATED PROTEIN ASSAY REAGENT, AND METHOD FOR STABILIZING GLYCATED PROTEIN ASSAY REAGENT | JONES-FOSTER, ERICA NICOLE | 1656 | §103 | Non-Final OA | — | Pending | Dec 28, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial